These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 10498451

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
    Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Pettersson E.
    N Engl J Med; 1998 Aug 06; 339(6):370-4. PubMed ID: 9691103
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm.
    Sandborn WJ, Feagan BG.
    Aliment Pharmacol Ther; 2003 Aug 01; 18(3):263-77. PubMed ID: 12895211
    [Abstract] [Full Text] [Related]

  • 7. The effectiveness of budesonide therapy for Crohn's disease.
    Kane SV, Schoenfeld P, Sandborn WJ, Tremaine W, Hofer T, Feagan BG.
    Aliment Pharmacol Ther; 2002 Aug 01; 16(8):1509-17. PubMed ID: 12182751
    [Abstract] [Full Text] [Related]

  • 8. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
    Mantzaris GJ, Petraki K, Sfakianakis M, Archavlis E, Christidou A, Chadio-Iordanides H, Triadaphyllou G.
    Clin Gastroenterol Hepatol; 2003 Mar 01; 1(2):122-8. PubMed ID: 15017504
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC, Hanauer S.
    Cochrane Database Syst Rev; 2010 Dec 08; (12):CD008870. PubMed ID: 21154400
    [Abstract] [Full Text] [Related]

  • 11. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
    Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Pettersson E, International Budesonide-Mesalazine Study Group.
    Am J Gastroenterol; 2002 Mar 08; 97(3):649-53. PubMed ID: 11922560
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Drug therapy of Crohn's disease: slowly increase or start aggressively right away?].
    Bischoff A.
    MMW Fortschr Med; 2010 Jan 14; 152(1-2):20. PubMed ID: 20302159
    [No Abstract] [Full Text] [Related]

  • 16. [New therapeutic modalities in Crohn's disease].
    Rachmilewitz D.
    Harefuah; 1999 Jun 15; 136(12):943-5. PubMed ID: 10955155
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Update on the management of Crohn's disease.
    Buchner AM, Blonski W, Lichtenstein GR.
    Curr Gastroenterol Rep; 2011 Oct 15; 13(5):465-74. PubMed ID: 21792543
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Treatment of joint pain in Crohn's patients with budesonide controlled ileal release.
    Florin TH, Graffner H, Nilsson LG, Persson T.
    Clin Exp Pharmacol Physiol; 2000 Apr 15; 27(4):295-8. PubMed ID: 10779128
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.